Weekly Movers

SAGE Clinical Trial Fails

September 28th, 2017

Sage Therapeutics announced disappointing results on its late-stage clinical trial of a brexanolone treament for a seizure disorder called super-refractory status epilepticus (SRSE). Right now there is no U.S. drug approved for the condition. Sonal...

Read More

Five-Day Trend Shows Markets Like HK Divestiture Plans

September 27th, 2017

On September 20, Halcon Resources (HK) announced plans to divest its remaining non-operated oil assets in the Williston Basin to an undisclosed company for $104 million. Halcon started selling assets in the Williston Basin earlier this year in order...

Read More

ALNM Holds Gains Over Five Days

September 27th, 2017

Alnylam Pharmaceuticals reported exciting stage 3 clinical trial results on September 20. Its drug, patisiran, treats a rare nerve disorder called familial amyloid polyneuropathy. Alnylam will seek regulatory approval for patisiran later this...

Read More

PDL BioPharma Announces Stock Repurchase

September 26th, 2017

PDL BioPharma (PDLI) announced on September 25 that its board of directors authorized a new stock repurchase program. PDL will be able to purchase up to $25 million worth of its common stock. The company has a market cap of $500 million, so this...

Read More

Interested in events that actually move the market?Awesome!

Let us send you a recap of every weeks market movers!

Better yet…Receive ALERTS
of Market Moving Events…
seconds after they surface!

  • Mergers & Acquisitions
  • Clinical Trials
  • Contract Awards
  • Stock Repurchase Programs
  • Earnings Announcement

Get Started